Mirabegron Zentiva

Mirabegron, the active ingredient in Mirabegron Zentiva, is a β3‑adrenergic receptor agonist presented as a tablet for oral use. It treats overactive bladder symptoms such as urinary urgency, frequency and urge incontinence in adults.

GNH USA supplies Mirabegron Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU marketing authorisation requirements and is manufactured under strict quality standards. It is available for bulk distribution to meet the needs of healthcare systems across multiple regions.

Mirabegron is used to manage conditions within the overactive bladder disease family.

Overactive bladder: improves bladder capacity and reduces urgency episodes. Urinary urgency: decreases the frequency of sudden urges to void. Urge urinary incontinence: lowers the number of incontinence episodes.

Adverse reactions reported with Mirabegron Zentiva are categorized by frequency.

Common Side Effects: - Hypertension: elevated blood pressure readings. - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Urinary tract infection: signs of bladder infection. - Headache: mild to moderate head pain. - Constipation: reduced bowel movements. - Dry mouth: decreased salivation.

Serious or Rare Side Effects: - Severe hypertension: markedly high blood pressure requiring medical attention. - Tachycardia: rapid heart rate that may be symptomatic. - Angioedema: swelling of face, lips or throat. - Urinary retention: difficulty emptying the bladder. - Allergic reactions: rash, itching or anaphylaxis. - Myocardial infarction: rare occurrence of heart attack.

When prescribing Mirabegron, clinicians should consider several safety measures.

Assess blood pressure before initiating: monitor regularly during therapy. Review cardiovascular history: use with caution in patients with uncontrolled hypertension. Evaluate renal function: dose adjustment may be needed in severe impairment. Consider drug interactions: avoid concomitant use with strong CYP2D6 inhibitors. Store at ambient temperature: keep in original container, protect from moisture and heat.

Mirabegron may interact with other medicines; awareness of interaction severity guides management.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): can increase mirabegron exposure. - MAO inhibitors: risk of hypertensive events. - Anticholinergic agents used for bladder control: may reduce efficacy.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma levels. - CYP3A4 inducers (e.g., rifampin): may lower effectiveness. - Antihypertensive drugs: mirabegron may attenuate blood‑pressure‑lowering effect.